surpass cvot tirzepatide results π‘ New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What Don't Miss a Beat: SURPASS-CVOT
Pay in 4 interest-free payments of $6.78 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 4 - Aug 9



00032-X/asset/f312f4e3-50d1-472f-90c9-896e4cef8e23/main.assets/gr1_lrg.jpg)








:max_bytes(150000):strip_icc()/Health-GettyImages-1675158771-70640c9fdf1b41078975cfc3fd538a6b.jpg)
















